Kohei Shitara

1 month ago | cell.com | Hui-Yan Luo |Yun-Xin Lu |Kohei Shitara |Heinz-Josef Lenz |Rui-hua Xu

Get full text accessLog in, subscribe or purchase for full access. References1. Bray, F. ∙ Laversanne, M. ∙ Sung, H. ... Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J. Clin. 2024; 74:229-2632. Sun, D. ∙ Gao, W. ∙ Hu, H. ... Why 90% of clinical drug development fails and how to improve it? Acta Pharm. Sin. B. 2022; 12:3049-30623. Wang, F. ∙ Ruan, D.-Y. ∙ Xu, R.-H.

May 22, 2024 | onclive.com | Kohei Shitara

May 22, 2024Kohei Shitara, MD, discusses the background of the phase 3 CheckMate 649 study in advanced gastric cancer, GEJ cancer, and esophageal adenocarcinoma.

Jan 22, 2024 | bpno.dk | Kohei Shitara

januar 2024 The four-year survival data from the CheckMate 649 study, revealed at the ASCO GI meeting, demonstrates the survival benefits of combining chemotherapy with nivolumab. This pivotal research supports the recommendation that this combination therapy should be adopted as the new standard of care for treating gastric and esophageal cancers.

Jan 22, 2024 | bpno.dk | Kohei Shitara

januar 2024 Nausea and vomiting emerged as the most frequent treatment-related adverse events among patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma treated with zolbetuximab plus chemotherapy. In this MEDtalk, Dr. Kohei Shitara elaborates the management strategies for these side effects.

Jan 20, 2024 | onclive.com | Kohei Shitara

January 20, 2024Kohei Shitara, MD, discusses first-line nivolumab plus chemotherapy vs chemotherapy alone in gastric cancer, GEJ cancer, or esophageal adenocarcinoma.